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Background
Phase I and - occasionally - also phase II metabolites may
contribute to the overall effect of a drug. This is not always
apparent or revealed, since total concentrations of metab-
olites may be low in relation to parent drug concentra-
tions. In the case of carvedilol, using a comparison of
HPLC and β1-specific radioligand receptor binding assay
(RRA), it was possible to demonstrate that regarding β-
adrenoceptor blockade the effect appears directly linked
to the serum compartment, which indicates instantane-
ous equilibrium between the blood compartment and the
biophase, and that oxidative metabolites significantly
contribute to the effect, particularly after oral administra-
tion. This drug serves as model compound in different
approaches for evaluating the role of formation of active
metabolites during first-pass when hepatic clearance var-
ies.
Methods
A kinetic model, which includes the immediate transfor-
mation of a fraction of the dose into active metabolites
during first-pass through the liver, i.e., before it reaches
the systemic circulation (AM-FP model), was found supe-
rior to standard models.
Results
Overall, both systemic and oral clearance values were dif-
ferent for the two carvedilol enantiomers: 27.5 L/h (R)
and 49.6 L/h (S) for i.v. administration, and 11.3 L/h (R)
and 21.6 L/h (S)  for p.o. administration. The hepatic
extraction ratio was estimated to approximately 0.76 and
0.77 for the (R)- and (S)-enantiomer, respectively.
Conclusion
For carvedilol, the hepatic extraction ratio is considerable,
and the oral availability (calculated assuming complete
absorption and no intestinal elimination) amounts to 25-
35% for the parent drug due to extensive first-pass metab-
olism. In spite of their low serum levels, the contribution
of the metabolites must not be neglected, especially for
oral dosing. Elimination of the parent drug was found to
be rate-limiting, i.e., the kinetics of the metabolites is for-
mation-rate-limited, at least in healthy volunteers. The
AM-FP model was most suitable, since parent drug and
metabolites appear to enter the systemic circulation
simultaneously. The new compartmental model is appli-
cable for PK/PD simulation studies including situations
where hepatic clearance is affected. It was used to simulate
the contribution of active metabolites formed during first-
pass to the overall effect, also under conditions of
impaired liver function leading to reduced metabolic
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clearance and in case of drug-drug interactions that are
hypothesized to induce absorption.